Atairgin Technologies

Atairgin Technologies was a biotechnology company specializing in the development of lipid-based diagnostics and therapeutics, with a specific focus on lysophosphatidic acid (LPA) signaling. The company's lead programs centered on the early detection of ovarian cancer using LPA as a blood-borne biomarker, aiming to improve survival rates through earlier intervention. In addition to diagnostics, Atairgin worked on small molecule inhibitors targeting LPA receptors and autotaxin to treat various cancers and inflammatory conditions. The company was founded based on research from the University of Utah and maintained operations in both California and Utah. Atairgin was acquired by Echelon Biosciences in 2004, which subsequently integrated the company's intellectual property into its broader lipid research and drug discovery platform.